The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth

Simple Summary The low survival rate of osteosarcoma (OS) patients underlines the urgency of developing new therapeutic strategies for this disease. In recent years, the important role of Hippo/YAP signaling in cancer has been evaluated, focusing on the possibility of targeting this signaling pathwa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2020-12, Vol.12 (12), p.3847, Article 3847
Hauptverfasser: Morice, Sarah, Mullard, Mathilde, Brion, Regis, Dupuy, Maryne, Renault, Sarah, Tesfaye, Robel, Brounais-Le Royer, Benedicte, Ory, Benjamin, Redini, Francoise, Verrecchia, Franck
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 12
container_start_page 3847
container_title Cancers
container_volume 12
creator Morice, Sarah
Mullard, Mathilde
Brion, Regis
Dupuy, Maryne
Renault, Sarah
Tesfaye, Robel
Brounais-Le Royer, Benedicte
Ory, Benjamin
Redini, Francoise
Verrecchia, Franck
description Simple Summary The low survival rate of osteosarcoma (OS) patients underlines the urgency of developing new therapeutic strategies for this disease. In recent years, the important role of Hippo/YAP signaling in cancer has been evaluated, focusing on the possibility of targeting this signaling pathway as an anti-cancer strategy. The aims of this work were (1) to identify a Hippo/YAP signature in OS patients, (2) to define the role of YAP in OS primary tumor growth, (3) to elucidate the role of TEAD in YAP-driven OS tumor growth in vivo, and (4) to evaluate the effects of verteporfin and CA3, two specific YAP-inhibitors, on the OS tumors growth. Our work identifies the YAP/TEAD axis as a promising therapeutic target in OS and demonstrates that verteporfin and CA3, through regulation of OS cells apoptosis, could be a promising therapeutic strategy for inhibiting OS primary tumor growth. Although some studies suggested that disruption of the Hippo signaling pathway is associated with osteosarcoma progression, the molecular mechanisms by which YAP regulates primary tumor growth is not fully clarified. In addition, the validation of YAP as a therapeutic target through the use of inhibitors in a preclinical model must be demonstrated. RNA-seq analysis and Kaplan-Meier assays identified a YAP signature in osteosarcoma patients and a correlation with patients' outcomes. Molecular and cellular analysis (RNAseq, PLA, immunoprecipitation, promoter/specific gene, proliferation, cell cycle assays) using overexpression of mutated forms of YAP able or unable to interact with TEAD, indicate that TEAD is crucial for YAP-driven cell proliferation and in vivo tumor growth. In addition, in vivo experiments using an orthotopic mice model of osteosarcoma show that two YAP/TEAD inhibitors, verteporfin and CA3, reduce primary tumor growth. In this context, in vitro experiments demonstrate that these inhibitors decrease YAP expression, YAP/TEAD transcriptional activity and cell viability mainly by their ability to induce cell apoptosis. We thus demonstrate that the YAP/TEAD signaling axis is a central actor in mediating primary tumor growth of osteosarcoma, and that the use of YAP inhibitors may be a promising therapeutic strategy against osteosarcoma tumor growth.
doi_str_mv 10.3390/cancers12123847
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7766439</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2476561592</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-b9c140109e63910bf1d9e6cbca6f7a32726f91afb84e7d4e3a11982bb2526cf73</originalsourceid><addsrcrecordid>eNqNks9rFDEUxwdRbKk9e5McFVk3vyaZeBCGcW2FxfYwCp6GTPalG9mdrEmma__7Zpm61J4MgTzyPu_7XvimKF4T_IExhedGDwZCJJRQVnH5rDilWNKZEIo_fxSfFOcx_sJ5MUakkC-LE8Y4UVSVp0Vq14B-1tfzdlF_RvUfF5HOG32DPcqpoHcwJmdQq8MNJOQGdBUT-KiD8Vv9ES2sBZOQt-gHhAQ7H2xm9LBCTc2QH9B1cFsd7lA7bn1AF8Hv0_pV8cLqTYTzh_Os-P5l0TaXs-XVxdemXs4MpzLNemUIxwQrEEwR3FuyyqHpjRZWakYlFVYRbfuKg1xxYJoQVdG-pyUVxkp2VnyadHdjv4WVgSEFvel200id1677NzO4dXfjbzspheBMZYF3k8D6SdllvewOd5hjUVa0uiWZffvQLPjfI8TUbV00sNnoAfwYO8qlKAUpFc3ofEJN8DEGsEdtgruDtd0Ta3PFm8cvOfJ_jczA-wnYQ-9tNA6ywBHL3gtMKePV4RscZq3-n25c0sn5ofHjkNg9Ci7AVA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476561592</pqid></control><display><type>article</type><title>The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Web of Science - Science Citation Index Expanded - 2020&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>PubMed Central</source><creator>Morice, Sarah ; Mullard, Mathilde ; Brion, Regis ; Dupuy, Maryne ; Renault, Sarah ; Tesfaye, Robel ; Brounais-Le Royer, Benedicte ; Ory, Benjamin ; Redini, Francoise ; Verrecchia, Franck</creator><creatorcontrib>Morice, Sarah ; Mullard, Mathilde ; Brion, Regis ; Dupuy, Maryne ; Renault, Sarah ; Tesfaye, Robel ; Brounais-Le Royer, Benedicte ; Ory, Benjamin ; Redini, Francoise ; Verrecchia, Franck</creatorcontrib><description>Simple Summary The low survival rate of osteosarcoma (OS) patients underlines the urgency of developing new therapeutic strategies for this disease. In recent years, the important role of Hippo/YAP signaling in cancer has been evaluated, focusing on the possibility of targeting this signaling pathway as an anti-cancer strategy. The aims of this work were (1) to identify a Hippo/YAP signature in OS patients, (2) to define the role of YAP in OS primary tumor growth, (3) to elucidate the role of TEAD in YAP-driven OS tumor growth in vivo, and (4) to evaluate the effects of verteporfin and CA3, two specific YAP-inhibitors, on the OS tumors growth. Our work identifies the YAP/TEAD axis as a promising therapeutic target in OS and demonstrates that verteporfin and CA3, through regulation of OS cells apoptosis, could be a promising therapeutic strategy for inhibiting OS primary tumor growth. Although some studies suggested that disruption of the Hippo signaling pathway is associated with osteosarcoma progression, the molecular mechanisms by which YAP regulates primary tumor growth is not fully clarified. In addition, the validation of YAP as a therapeutic target through the use of inhibitors in a preclinical model must be demonstrated. RNA-seq analysis and Kaplan-Meier assays identified a YAP signature in osteosarcoma patients and a correlation with patients' outcomes. Molecular and cellular analysis (RNAseq, PLA, immunoprecipitation, promoter/specific gene, proliferation, cell cycle assays) using overexpression of mutated forms of YAP able or unable to interact with TEAD, indicate that TEAD is crucial for YAP-driven cell proliferation and in vivo tumor growth. In addition, in vivo experiments using an orthotopic mice model of osteosarcoma show that two YAP/TEAD inhibitors, verteporfin and CA3, reduce primary tumor growth. In this context, in vitro experiments demonstrate that these inhibitors decrease YAP expression, YAP/TEAD transcriptional activity and cell viability mainly by their ability to induce cell apoptosis. We thus demonstrate that the YAP/TEAD signaling axis is a central actor in mediating primary tumor growth of osteosarcoma, and that the use of YAP inhibitors may be a promising therapeutic strategy against osteosarcoma tumor growth.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers12123847</identifier><identifier>PMID: 33419295</identifier><language>eng</language><publisher>BASEL: Mdpi</publisher><subject>Cancer ; Life Sciences ; Life Sciences &amp; Biomedicine ; Oncology ; Science &amp; Technology</subject><ispartof>Cancers, 2020-12, Vol.12 (12), p.3847, Article 3847</ispartof><rights>Attribution</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>29</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000602234800001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c427t-b9c140109e63910bf1d9e6cbca6f7a32726f91afb84e7d4e3a11982bb2526cf73</citedby><cites>FETCH-LOGICAL-c427t-b9c140109e63910bf1d9e6cbca6f7a32726f91afb84e7d4e3a11982bb2526cf73</cites><orcidid>0000-0002-5692-5980 ; 0000-0003-4920-2554 ; 0000-0002-4556-9853 ; 0000-0003-2358-219X ; 0000-0002-2622-7356</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766439/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766439/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,28253,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33419295$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://nantes-universite.hal.science/hal-04065828$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Morice, Sarah</creatorcontrib><creatorcontrib>Mullard, Mathilde</creatorcontrib><creatorcontrib>Brion, Regis</creatorcontrib><creatorcontrib>Dupuy, Maryne</creatorcontrib><creatorcontrib>Renault, Sarah</creatorcontrib><creatorcontrib>Tesfaye, Robel</creatorcontrib><creatorcontrib>Brounais-Le Royer, Benedicte</creatorcontrib><creatorcontrib>Ory, Benjamin</creatorcontrib><creatorcontrib>Redini, Francoise</creatorcontrib><creatorcontrib>Verrecchia, Franck</creatorcontrib><title>The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth</title><title>Cancers</title><addtitle>CANCERS</addtitle><addtitle>Cancers (Basel)</addtitle><description>Simple Summary The low survival rate of osteosarcoma (OS) patients underlines the urgency of developing new therapeutic strategies for this disease. In recent years, the important role of Hippo/YAP signaling in cancer has been evaluated, focusing on the possibility of targeting this signaling pathway as an anti-cancer strategy. The aims of this work were (1) to identify a Hippo/YAP signature in OS patients, (2) to define the role of YAP in OS primary tumor growth, (3) to elucidate the role of TEAD in YAP-driven OS tumor growth in vivo, and (4) to evaluate the effects of verteporfin and CA3, two specific YAP-inhibitors, on the OS tumors growth. Our work identifies the YAP/TEAD axis as a promising therapeutic target in OS and demonstrates that verteporfin and CA3, through regulation of OS cells apoptosis, could be a promising therapeutic strategy for inhibiting OS primary tumor growth. Although some studies suggested that disruption of the Hippo signaling pathway is associated with osteosarcoma progression, the molecular mechanisms by which YAP regulates primary tumor growth is not fully clarified. In addition, the validation of YAP as a therapeutic target through the use of inhibitors in a preclinical model must be demonstrated. RNA-seq analysis and Kaplan-Meier assays identified a YAP signature in osteosarcoma patients and a correlation with patients' outcomes. Molecular and cellular analysis (RNAseq, PLA, immunoprecipitation, promoter/specific gene, proliferation, cell cycle assays) using overexpression of mutated forms of YAP able or unable to interact with TEAD, indicate that TEAD is crucial for YAP-driven cell proliferation and in vivo tumor growth. In addition, in vivo experiments using an orthotopic mice model of osteosarcoma show that two YAP/TEAD inhibitors, verteporfin and CA3, reduce primary tumor growth. In this context, in vitro experiments demonstrate that these inhibitors decrease YAP expression, YAP/TEAD transcriptional activity and cell viability mainly by their ability to induce cell apoptosis. We thus demonstrate that the YAP/TEAD signaling axis is a central actor in mediating primary tumor growth of osteosarcoma, and that the use of YAP inhibitors may be a promising therapeutic strategy against osteosarcoma tumor growth.</description><subject>Cancer</subject><subject>Life Sciences</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Oncology</subject><subject>Science &amp; Technology</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqNks9rFDEUxwdRbKk9e5McFVk3vyaZeBCGcW2FxfYwCp6GTPalG9mdrEmma__7Zpm61J4MgTzyPu_7XvimKF4T_IExhedGDwZCJJRQVnH5rDilWNKZEIo_fxSfFOcx_sJ5MUakkC-LE8Y4UVSVp0Vq14B-1tfzdlF_RvUfF5HOG32DPcqpoHcwJmdQq8MNJOQGdBUT-KiD8Vv9ES2sBZOQt-gHhAQ7H2xm9LBCTc2QH9B1cFsd7lA7bn1AF8Hv0_pV8cLqTYTzh_Os-P5l0TaXs-XVxdemXs4MpzLNemUIxwQrEEwR3FuyyqHpjRZWakYlFVYRbfuKg1xxYJoQVdG-pyUVxkp2VnyadHdjv4WVgSEFvel200id1677NzO4dXfjbzspheBMZYF3k8D6SdllvewOd5hjUVa0uiWZffvQLPjfI8TUbV00sNnoAfwYO8qlKAUpFc3ofEJN8DEGsEdtgruDtd0Ta3PFm8cvOfJ_jczA-wnYQ-9tNA6ywBHL3gtMKePV4RscZq3-n25c0sn5ofHjkNg9Ci7AVA</recordid><startdate>20201220</startdate><enddate>20201220</enddate><creator>Morice, Sarah</creator><creator>Mullard, Mathilde</creator><creator>Brion, Regis</creator><creator>Dupuy, Maryne</creator><creator>Renault, Sarah</creator><creator>Tesfaye, Robel</creator><creator>Brounais-Le Royer, Benedicte</creator><creator>Ory, Benjamin</creator><creator>Redini, Francoise</creator><creator>Verrecchia, Franck</creator><general>Mdpi</general><general>MDPI</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5692-5980</orcidid><orcidid>https://orcid.org/0000-0003-4920-2554</orcidid><orcidid>https://orcid.org/0000-0002-4556-9853</orcidid><orcidid>https://orcid.org/0000-0003-2358-219X</orcidid><orcidid>https://orcid.org/0000-0002-2622-7356</orcidid></search><sort><creationdate>20201220</creationdate><title>The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth</title><author>Morice, Sarah ; Mullard, Mathilde ; Brion, Regis ; Dupuy, Maryne ; Renault, Sarah ; Tesfaye, Robel ; Brounais-Le Royer, Benedicte ; Ory, Benjamin ; Redini, Francoise ; Verrecchia, Franck</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-b9c140109e63910bf1d9e6cbca6f7a32726f91afb84e7d4e3a11982bb2526cf73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer</topic><topic>Life Sciences</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Oncology</topic><topic>Science &amp; Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morice, Sarah</creatorcontrib><creatorcontrib>Mullard, Mathilde</creatorcontrib><creatorcontrib>Brion, Regis</creatorcontrib><creatorcontrib>Dupuy, Maryne</creatorcontrib><creatorcontrib>Renault, Sarah</creatorcontrib><creatorcontrib>Tesfaye, Robel</creatorcontrib><creatorcontrib>Brounais-Le Royer, Benedicte</creatorcontrib><creatorcontrib>Ory, Benjamin</creatorcontrib><creatorcontrib>Redini, Francoise</creatorcontrib><creatorcontrib>Verrecchia, Franck</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morice, Sarah</au><au>Mullard, Mathilde</au><au>Brion, Regis</au><au>Dupuy, Maryne</au><au>Renault, Sarah</au><au>Tesfaye, Robel</au><au>Brounais-Le Royer, Benedicte</au><au>Ory, Benjamin</au><au>Redini, Francoise</au><au>Verrecchia, Franck</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth</atitle><jtitle>Cancers</jtitle><stitle>CANCERS</stitle><addtitle>Cancers (Basel)</addtitle><date>2020-12-20</date><risdate>2020</risdate><volume>12</volume><issue>12</issue><spage>3847</spage><pages>3847-</pages><artnum>3847</artnum><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Simple Summary The low survival rate of osteosarcoma (OS) patients underlines the urgency of developing new therapeutic strategies for this disease. In recent years, the important role of Hippo/YAP signaling in cancer has been evaluated, focusing on the possibility of targeting this signaling pathway as an anti-cancer strategy. The aims of this work were (1) to identify a Hippo/YAP signature in OS patients, (2) to define the role of YAP in OS primary tumor growth, (3) to elucidate the role of TEAD in YAP-driven OS tumor growth in vivo, and (4) to evaluate the effects of verteporfin and CA3, two specific YAP-inhibitors, on the OS tumors growth. Our work identifies the YAP/TEAD axis as a promising therapeutic target in OS and demonstrates that verteporfin and CA3, through regulation of OS cells apoptosis, could be a promising therapeutic strategy for inhibiting OS primary tumor growth. Although some studies suggested that disruption of the Hippo signaling pathway is associated with osteosarcoma progression, the molecular mechanisms by which YAP regulates primary tumor growth is not fully clarified. In addition, the validation of YAP as a therapeutic target through the use of inhibitors in a preclinical model must be demonstrated. RNA-seq analysis and Kaplan-Meier assays identified a YAP signature in osteosarcoma patients and a correlation with patients' outcomes. Molecular and cellular analysis (RNAseq, PLA, immunoprecipitation, promoter/specific gene, proliferation, cell cycle assays) using overexpression of mutated forms of YAP able or unable to interact with TEAD, indicate that TEAD is crucial for YAP-driven cell proliferation and in vivo tumor growth. In addition, in vivo experiments using an orthotopic mice model of osteosarcoma show that two YAP/TEAD inhibitors, verteporfin and CA3, reduce primary tumor growth. In this context, in vitro experiments demonstrate that these inhibitors decrease YAP expression, YAP/TEAD transcriptional activity and cell viability mainly by their ability to induce cell apoptosis. We thus demonstrate that the YAP/TEAD signaling axis is a central actor in mediating primary tumor growth of osteosarcoma, and that the use of YAP inhibitors may be a promising therapeutic strategy against osteosarcoma tumor growth.</abstract><cop>BASEL</cop><pub>Mdpi</pub><pmid>33419295</pmid><doi>10.3390/cancers12123847</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-5692-5980</orcidid><orcidid>https://orcid.org/0000-0003-4920-2554</orcidid><orcidid>https://orcid.org/0000-0002-4556-9853</orcidid><orcidid>https://orcid.org/0000-0003-2358-219X</orcidid><orcidid>https://orcid.org/0000-0002-2622-7356</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2020-12, Vol.12 (12), p.3847, Article 3847
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7766439
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central
subjects Cancer
Life Sciences
Life Sciences & Biomedicine
Oncology
Science & Technology
title The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T09%3A57%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20YAP/TEAD%20Axis%20as%20a%20New%20Therapeutic%20Target%20in%20Osteosarcoma:%20Effect%20of%20Verteporfin%20and%20CA3%20on%20Primary%20Tumor%20Growth&rft.jtitle=Cancers&rft.au=Morice,%20Sarah&rft.date=2020-12-20&rft.volume=12&rft.issue=12&rft.spage=3847&rft.pages=3847-&rft.artnum=3847&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers12123847&rft_dat=%3Cproquest_pubme%3E2476561592%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476561592&rft_id=info:pmid/33419295&rfr_iscdi=true